Gilead Sciences 2012 Annual Report Download - page 10

Derek Marshall, Research Scientist, Biology, Gilead Sciences
Vivian Barry, Associate Scientist, Biology, Gilead Sciences
Rhyannon Spangler, Senior Research Associate, Biology,
Gilead Sciences
PHASE 3
IDELALISIB (PI3K DELTA INHIBITOR)
POTENTIAL INDICATION: CHRONIC LYMPHOCYTIC
LEUKEMIA
IDELALISIB (PI3K DELTA INHIBITOR)
POTENTIAL INDICATION: INDOLENT NON-HODGKIN’S
LYMPHOMA
PHASE 2
MOMELOTINIB (JAK INHIBITOR)
POTENTIAL INDICATION: MYELOFIBROSIS
SIMTUZUMAB (MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: MYELOFIBROSIS
SIMTUZUMAB (MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: PANCREATIC CANCER
SIMTUZUMAB (MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: COLORECTAL CANCER
GS-9820 (PI3K DELTA INHIBITOR)
POTENTIAL INDICATION: LYMPHOID MALIGNANCIES
PHASE 1
GS-9973* (SYK INHIBITOR)
POTENTIAL INDICATION: B-CELL MALIGNANCIES
* Being developed as a single agent and in combination with idelalisib.
Oncology and inflammation are newer focus areas for
Gilead. We are making rapid progress in identifying
targeted investigational cancer therapies and evaluating
them in clinical studies.
Our lead oncology candidates include idelalisib (GS-
1101) and momelotinib (GS-0387/CYT-0387). Idelalisib
is a small molecule drug designed to inhibit the PI3K
delta signaling pathway that is thought to drive certain
cancer cell development. The compound is being stud-
ied in clinical trials for chronic lymphocytic leukemia
and indolent non-Hodgkin’s lymphoma. Momelotinib is
an investigational JAK inhibitor that has shown promise
for the treatment of myelofibrosis, a blood disorder. This
molecule was added to Gilead’s development pipeline
through the acquisition of YM BioSciences.
Simtuzumab (GS-6624) is the first monoclonal antibody
developed to target LOXL2, an enzyme thought to be
involved in solid tumor growth. It is being studied for
pancreatic and colorectal cancers and myelofibrosis.
In addition, GS-9973, our SYK inhibitor, is in clinical
studies for B-cell malignancies.
Through partnerships, we are exploring new therapeutic
targets in oncology. Our multi-year collaboration with
Yale School of Medicine is searching for the genetic
basis and underlying molecular mechanisms of many
forms of cancer.
FOCUS AREA
ONCOLOGY/
INFLAMMATION
Anne Mathew, Director, Marketing, Gilead Sciences
PHASE 3
AZTREONAM FOR INHALATION SOLUTION
POTENTIAL INDICATION: NON-CF BRONCHIECTASIS
PHASE 2
SIMTUZUMAB (MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: IDIOPATHIC PULMONARY
FIBROSIS
GS-5806
POTENTIAL INDICATION: RESPIRATORY SYNCYTIAL
VIRUS
Gilead’s first product in the category of respiratory
disease, Tamiflu,
® remains the leading antiviral for
treatment and prevention of seasonal influenza.
Our inhaled antibiotic, Cayston,
® is indicated to treat
respiratory Pseudomonas aeruginosa in people with
cystic fibrosis (CF), an inherited disease that affects
the lungs and digestive system. We are also investigating
the potential for Cayston to treat bacterial infections in
people with non-CF bronchiectasis.
Simtuzumab (GS-6624) is a monoclonal antibody being
investigated for the potential treatment of idiopathic
pulmonary fibrosis, a life-threatening scarring of the
lungs that has no known cause. GS-5806 is being studied
for respiratory syncytial virus (RSV), which infects the
human respiratory tract and can lead to bronchiolitis
and pneumonia. RSV is the most common microbial
cause of lung and airway infections in infants and
young children.
FOCUS AREA
RESPIRATORY
DISEASE
1716